You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,585,890

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,585,890

Title:	Pharmaceutical compositions comprising flavonoids and menthol
Abstract:	The present invention relates to use of certain antiviral fragrances for reduction of viruses, in particular vira causing common cold. In one embodiment, the invention relates to pharmaceutical compositions comprising an antiviral fragrance, preferably menthol. Said compositions preferably also comprise one or more flavonoids. The invention also relates to treatment of common cold using said compositions.
Inventor(s):	Berg; Kurt Frimann (Charlottenlund, DK)
Assignee:	Immunpharm A/S (Alborg O, DK)
Application Number:	10/532,341
Patent Claims:	1. A pharmaceutical composition comprising one or more purified flavonoids; and purified menthol, in a state of purity such that the purified menthol has a direct antiviral effect in vitro on rhinovirus in WISH cells, or potentiates the antiviral effect in vitro of human interferon -.alpha.-2b (Intron A) on rhinovirus in WISH cells. 2. The pharmaceutical composition according to claim 1, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt. 3. The pharmaceutical composition according to claim 2, wherein said metal is zinc. 4. The pharmaceutical composition according to claim 2, wherein the metal is zinc selected from the group consisting of Zn.sup.2+ aminochelates , Zn.sup.2+ amino acid chelates, Zn(acetate).sub.2, Zn.sup.2+ DL-methionine, Zn.sup.2+ L-methionine, ZnGluconate and PolaPreZinc.RTM.. 5. The pharmaceutical composition according to claim 1, wherein said composition is useful for oral and/or nasal administration. 6. The pharmaceutical composition according to claim 1, wherein said composition is selected from the group consisting of lozenges, troches, capsules, syrups, tablets, lollipops, solutions, dispersions, suspensions, powders, micropheres, chewing tablets, chewing gums, sprays, droppers, pipettes and pills. 7. The pharmaceutical composition according to claim 1, wherein said composition is a slow-release composition. 8. The pharmaceutical composition according to claim 1, wherein said composition is lozenges. 9. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of crude plant extracts. 10. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of other terpenes than menthol. 11. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of one or more compounds selected from the group consisting of menthone, menthyl acetate, limonene and neomenthol. 12. The pharmaceutical composition according to claim 1, wherein one or more flavonoids are chelating a metal. 13. The pharmaceutical composition according to claim 1, wherein the metal is Zn.sup.2+. 14. The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of flavonoids of the general formula: ##STR00007## and the general formula: ##STR00008## Wherein R2' can be selected from: --H --OH R3' can be selected from: --H --OH --OCH.sub.3 --OCH.sub.2CH.sub.2OH R4' can be selected from: --H --OH --OCH.sub.3 --OCH.sub.2CH.sub.2OH R5' can be selected from: --H --OH --OCH.sub.3 --OCH.sub.2CH.sub.2OH R6' is --H; R3 including R3.sub.1 and R3.sub.2 can individually be selected from: --H --OH --O-rutinose --O-glucoside --O-glucose-p-coumaric acid --SOH --O-rhamnose R4 can be selected from: --(O) --OH R5 can be selected from: --H --OH --O--CH.sub.2CH.sub.2OH R6 can be selected from: --H --OH --OCH.sub.3 R7 can be selected from: --H --OH --O-glucose --OCH.sub.3 --OCH.sub.2CH.sub.2OH --O-glucuronic acid --O-rutinose --O-rhamnoglucoside R8 can be selected from: --H --OH. 15. The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of troxerutin, venoruton, hesperitin, naringenin, nobiletin, tangeritin, baicalein, galangin, genistein, quercetin, apigenin, kaempferol, fisetin, rutin, luteolin, chrysin, taxifolin, eriodyctol, catecithin, epicatechin gallate, epigallocatechin gallate, flavone, sideritoflavone, hypolaetin-8-O-Gl, oroxindin, 3-hydroxyflavone, morin, quercetagetin-7-O-Gl, tarnbuletin, gossypin, hipifolin, naringin, leucocyanidol, amentoflavone and derivatives thereof and mixtures thereof. 16. The pharmaceutical composition according to claim 1, wherein said flavonoid is not a naturally occurring flavonoid. 17. The pharmaceutical composition according to claim 1, wherein said flavonoid is a rutoside. 18. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a rutoside aglycone. 19. The pharmaceutical composition according to claim 1, wherein said flavonoid is a hydroxyethylrutoside. 20. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a hydroxyethythyrutoside aglycone. 21. The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of hydroxyethylrutosides. 22. The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of mono-, di-, tri- and tetrahydroxyethylrutosides. 23. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is troxerutin. 24. The pharmaceutical composition according to claim 1, where at least one flavonoid is troxerutin aglycone. 25. The pharmaceutical composition according to claim 1, wherein the flavonoid is veneruton. 26. The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 90% pure. 27. The pharmaceutical composition according to claim 1, wherein the composition is in a form suitable for nasal administration. 28. The pharmaceutical composition according to claim 27, wherein the composition is in a form suitable for aerosol administration. 29. The pharmaceutical composition according to claim 28, wherein the composition is provided in a pressurized pack which further comprises a propellant. 30. The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 98% pure.

Details for Patent 7,585,890

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2022-10-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2022-10-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2022-10-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.